Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese HSK 1 – For Medical Students & Physicians A complete 20-lesson, 300-page Chinese HSK 1 course with a companion app in 21 languages — free forever. Arabic, Bengali, Dutch, English, Farsi, French, German, Hindi, Indonesian, Italian, Japanese, Korean, Portuguese, Russian, Spanish, Tagalog, Thai, Turkish, Ukrainian, Urdu, Vietnamese. By Bernd Sebastian Kamps and Andrea Melis

Inflammatory Bowel Diseases

Free Subscription 06.04.2026 4 Aliment Pharmacol Ther 2 Am J Gastroenterol 3 BMC Gastroenterol 1 Clin Gastroenterol Hepatol 4 Dig Dis Sci 2 Dis Colon Rectum 1 Gastroenterology 3 Inflamm Bowel Dis 2 J Crohns Colitis 1 J Pediatr 1 Minerva Gastroenterol (Torino) 1 PLoS One 2 Scand J Gastroenterol

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aliment Pharmacol Ther

1. HEGDE Y, Caldera F
   Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease - Expanding Strategies Beyond Double-Dose Recombinant Vaccination.
   Aliment Pharmacol Ther. 2026 Mar 31. doi: 10.1111/apt.70651.
   PubMed        
   
   
2. JIAO L, Cao Y
   Letter: Are All Extra-Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story?
   Aliment Pharmacol Ther. 2026 Mar 31. doi: 10.1111/apt.70650.
   PubMed        
   
   
3. BARBERIO B, Savarino EV
   Letter: The Persistence of Anxiety and Depression in Inflammatory Bowel Disease: A Core Phenotype Beyond Inflammatory Activity.
   Aliment Pharmacol Ther. 2026 Mar 31. doi: 10.1111/apt.70641.
   PubMed        
   
   
4. ALSOUDANI A, Swaminathan A
   Editorial: Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulising Crohn's Disease.
   Aliment Pharmacol Ther. 2026 Mar 30. doi: 10.1111/apt.70640.
   PubMed        
   
   

   
   Am J Gastroenterol

5. GOODWIN SW, Vuyyuru SK, Sedano R, Zou G, et al
   An Enhanced Treatment Algorithm Targeting Mucosal Healing is Effective and Safe in Older Patients with Crohn's Disease: A Post-hoc Analysis of the REACT2 Trial.
   Am J Gastroenterol. 2026 Apr 3. doi: 10.14309/ajg.0000000000004015.
   PubMed         Abstract available
   
   
6. GROSS SA, Shaukat A, Afzali A, Ahn JC, et al
   Artificial Intelligence for Gastroenterology Practice: A Modified Delphi Consensus.
   Am J Gastroenterol. 2026;121:1017-1024.
   PubMed         Abstract available
   
   

   
   BMC Gastroenterol

7. SOBOLEWSKA-WLODARCZYK A, Orlinski J, Witas Z, Wozniak L, et al
   Real-world utility of platelet count, hemoglobin, and iron levels as predictors of clinical response to vedolizumab in patients with ulcerative colitis: a retrospective, single-center study in Poland.
   BMC Gastroenterol. 2026 Apr 2. doi: 10.1186/s12876-026-04780.
   PubMed        
   
   
8. KIM H, Kim YZ, Kim SY, Choe YH, et al
   Factors associated with low bone mineral density at diagnosis in pediatric Crohn's disease: a large retrospective cohort study.
   BMC Gastroenterol. 2026 Apr 2. doi: 10.1186/s12876-026-04777.
   PubMed        
   
   
9. KAWAKAMI A, Tanaka M, Sakagami K, Ito H, et al
   Factors associated with urgent consultation recommendations for patients with inflammatory bowel disease calling a telephone service about worsening symptoms: a secondary analysis.
   BMC Gastroenterol. 2026 Mar 27. doi: 10.1186/s12876-026-04748.
   PubMed        
   
   

   
   Clin Gastroenterol Hepatol

10. ALLEZ M, Bak MTJ, Brand S, Diebakate-Scordamaglia L, et al
    Development and external validation of a predictive model for postoperative recurrence of Crohn's disease in the biologic era.
    Clin Gastroenterol Hepatol. 2026 Mar 27:S1542-3565(26)00220.
    PubMed         Abstract available
    
    

    
    Dig Dis Sci

11. CHEN NY, Chuang CH
    Dosing 5-ASA for Ulcerative Colitis: Is the Maximum Optimum?
    Dig Dis Sci. 2026 Apr 2. doi: 10.1007/s10620-026-09874.
    PubMed        
    
    
12. VADARLIS A, Germanidis G, Maris T, Pramateftakis MG, et al
    Investigating Handgrip Strength as a Practical Biomarker for Therapeutic Endpoints and Nutritional Status in Patients with Inflammatory Bowel Disease.
    Dig Dis Sci. 2026 Apr 1. doi: 10.1007/s10620-026-09880.
    PubMed         Abstract available
    
    
13. COHEN-MEKELBURG S, Hodish G, Ebner D, Resnicow K, et al
    The Multiple Dimensions of Self-Management in Active Inflammatory Bowel Disease: A Qualitative Analysis of Patients' Daily Lived Experiences.
    Dig Dis Sci. 2026 Mar 31. doi: 10.1007/s10620-026-09858.
    PubMed         Abstract available
    
    
14. LEAKE A, Bishara M, Lo SW, Tacey M, et al
    The SILVER Platter for Patients with Inflammatory Bowel Disease (IBD): An IBD Pharmacy Technician-Led Subcutaneous Biologic Home Delivery Service Is Associated with Sustained Improvement in Adherence and Active Health Management.
    Dig Dis Sci. 2026 Mar 27. doi: 10.1007/s10620-026-09785.
    PubMed         Abstract available
    
    

    
    Dis Colon Rectum

15. PRIEN C, Holubar SD
    Intersphincteric Proctectomy for Fistulizing Perianal Crohn's Disease.
    Dis Colon Rectum. 2026 Apr 1. doi: 10.1097/DCR.0000000000004158.
    PubMed        
    
    
16. ASHBURN JH
    Expert Commentary on Ulcerative Colitis-Associated Neoplasia.
    Dis Colon Rectum. 2026 Mar 27. doi: 10.1097/DCR.0000000000004239.
    PubMed        
    
    

    
    Gastroenterology

17. BURISCH J
    Re-induction or Redirection? Lessons From the REScUE Trial on Ustekinumab Intensification in Crohn's Disease.
    Gastroenterology. 2026 Mar 27:S0016-5085(26)00305.
    PubMed        
    
    

    
    Inflamm Bowel Dis

18. ARZIVIAN A, Rubin DT, Seow CH, Kerkham A, et al
    The Risk of Relapse Associated With Discontinuation of 5-Aminosalicylates in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
    Inflamm Bowel Dis. 2026;32:661-676.
    PubMed         Abstract available
    
    
19. SINGH S, Oliver BJ, Hou JK, Lum D, et al
    Real-World Implementation of Treat to Target in Patients With IBD in a Learning Health System: An IBD Qorus Collaborative Study.
    Inflamm Bowel Dis. 2026;32:702-710.
    PubMed         Abstract available
    
    
20. WARD TM, Unal E, Kirschling S, Giri B, et al
    Penetrating ileocolic Crohn disease with intra-abdominal abscess: diagnose, drugs, drain, divert?
    Inflamm Bowel Dis. 2026 Mar 31:izag030. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Crohns Colitis

21. DIMOPOULOS-VERMA A, Kulkarni C, Pike CW, Gombar S, et al
    Statin use is associated with lower rates of stricture development in patients with Crohn's disease: a propensity score-matched study of two nationwide population databases.
    J Crohns Colitis. 2026;20:jjag034.
    PubMed         Abstract available
    
    
22. MOREIRA PL, Dignass A, Estevinho MM, Santiago M, et al
    Timing matters: recommendations for outcome assessment in real-world evidence studies of Crohn's disease.
    J Crohns Colitis. 2026;20:jjag030.
    PubMed         Abstract available
    
    

    
    J Pediatr

23. GORDON RJ, Vishwanath V, Lavoie A, Mishra R, et al
    Efficacy and Safety of Titrated High-Dose Cholecalciferol Supplementation in Children and Young Adult Patients with Inflammatory Bowel Disease.
    J Pediatr. 2026 Mar 30:115084. doi: 10.1016/j.jpeds.2026.115084.
    PubMed         Abstract available
    
    

    
    Minerva Gastroenterol (Torino)

24. ZIFMAN E, Schujovitzky D, Galai T
    The effect of hypochlorous acid on urine color among pediatric ulcerative colitis patients treated with mesalamine.
    Minerva Gastroenterol (Torino). 2026 Apr 2. doi: 10.23736/S2724-5985.26.04114.
    PubMed         Abstract available
    
    

    
    PLoS One

25. WEIGEL C, Loosen SH, Yaqubi K, May P, et al
    Twelve?month rehospitalization after IBD?related hospitalization in Germany: A retrospective cohort study using administrative hospital data.
    PLoS One. 2026;21:e0346270.
    PubMed         Abstract available
    
    

    
    Scand J Gastroenterol

26. BERGSMARK C, Kristensen VA, Sjamo MB, Hoivik ML, et al
    Therapeutic drug monitoring in inflammatory bowel disease patients switching from intravenous to subcutaneous infliximab: insights from a prospective real-world study.
    Scand J Gastroenterol. 2026 Mar 28:1-11. doi: 10.1080/00365521.2026.2645083.
    PubMed         Abstract available
    
    
27. BUHL E, Kraaer MT, Kjeldsen J, Ainsworth MA, et al
    Personalised treatment in biologically naive patients with Crohn's disease: a systematic review of the last 10 years.
    Scand J Gastroenterol. 2026 Mar 28:1-18. doi: 10.1080/00365521.2026.2645095.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum